A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs NLG 802 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 27 Jul 2017 According to a NewLink Genetics Corporationmedia release, first patient has been dosed.
- 05 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.